BG
CNTA

Bellevue Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Bellevue Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$359K Buy
+9,030
New +$231K 0.01% 118

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bellevue Group's CNTA Position: Q1 2026 in Review

Bellevue Group opened a new position in Centessa Pharmaceuticals (CNTA) in Q1 2026: 9,030 shares worth $359K. The stake represents 0.01% of the portfolio and ranks #118 among its holdings.

161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Bellevue Group held 9,030 shares of Centessa Pharmaceuticals worth $359K as of Q1 2026.
  • Centessa Pharmaceuticals was a new Bellevue Group position in Q1 2026.
  • Centessa Pharmaceuticals made up 0.01% of Bellevue Group's portfolio in Q1 2026, its #118 holding.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.